Filella X, Alcover J, Molina R, Carrere W, Carretero P, Ballesta A M
Department of Clinical Biochemistry, (Unit Cancer Research), Hospital Clínic i Provincial, Barcelona, Spain.
Tumour Biol. 1996;17(1):20-6. doi: 10.1159/000217963.
To evaluate the diagnostic usefulness of prostate-specific antigen density (PSAD) in prostate cancer (PC) prostate-specific antigen (PSA) concentrations were measured in 175 patients with benign prostatic hypertrophy (BPH) and 50 patients with PC. Patients with BPH were classified according to the presence of complications of the disease: urinary infection or the presence of a bladder catheter. PSAD levels were observed to be greater than 0.15 in 3% of the patients with uncomplicated BPH and in 40% of the patients with complicated BPH. PSA levels were higher than 10 micrograms/l in 3 and 27% of these patients, respectively. High levels of PSAD were observed in 80% of the patients with cancer. Sixty-four percent of the patients with cancer presented PSA levels greater than 10 micrograms/l. These results indicate that PSAD is a useful parameter in the differential diagnosis of PC and BPH with the diagnostic efficacy of PSAD being greater than that of the serum determination of PSA.
为评估前列腺特异性抗原密度（PSAD）在前列腺癌（PC）诊断中的应用价值，对175例良性前列腺增生（BPH）患者和50例PC患者进行了前列腺特异性抗原（PSA）浓度测定。BPH患者根据疾病并发症情况分类：是否存在尿路感染或膀胱导管。无并发症BPH患者中3%、有并发症BPH患者中40%的PSAD水平高于0.15。这些患者中，PSA水平分别有3%和27%高于10微克/升。80%的癌症患者PSAD水平较高。64%的癌症患者PSA水平高于10微克/升。这些结果表明，PSAD在PC和BPH的鉴别诊断中是一个有用的参数，其诊断效能大于血清PSA测定。
